Financials Trend thinks that InMed is a "four-bagger" of an investment thanks to proven expertise, a proprietary cutting-edge technology and TWO drugs already heading towards clinical trials that could quickly position InMed as a major player.
From Financials Trend:
The biotech sector is well known for delivering triple-digit, quadruple-digit and even quintuple-digit stock winners. It’s not uncommon for a biotech company to go from relative unknown status to $ Billions in market value literally overnight. It’s the nature of the game for the biopharma industry and it holds true for our next hot pick, InMed Pharmaceutical (OTCMKTS:IMLFF)
The majority of biotech companies start off as primarily research, with no revenue and very little entry into the development phases… and that’s what sets InMed Pharmaceuticals apart. Proven expertise, a proprietary cutting-edge technology and TWO drugs already heading towards clinical trials could quickly position InMed as a major player.
Inmed Pharmaceutical Progresses Toward Cannabinoid-Based Drug Therapies
Inmed Pharmaceutical (CSE: IN; OTC: ILMFF) appears to be making progress towards the development of Cannabinoid-based drug therapies after announcing on October 3, 2017 that it had filed a provisional patent on its pain therapy application using synthesized cannabinoids verses extracts from the plant.
On October 17, 2017 ILMFF updated investors on its pain relief study saying that the results from these studies suggest that peripheral application of certain cannabinoid compounds, alone or in combination, is effective in the treatment of craniofacial muscle pain disorders, without any observed CNS side effects, and may be a more desirable strategy than systemic pain-relief administration.
READ THE FULL ARTICLE AND ANALYSIS AT FINANCIALS TREND
Disclaimer:
The information contained in this page/e-mail and in other Seed Investor communications are intended for general information purposes only. Seed Investor has not taken into account the specific investment objectives of any particular investor. You should always seek the counsel of a professional financial advisor before purchasing or selling stock. Seed Investor believes the sources of information to be reliable but Seed Investor does not guarantee the accuracy or completeness of the information provided on this website or in other Seed Investor communications, and expressly disclaims liability for any errors or omissions that may be contained in the information. (Read full disclaimer) Please see full disclaimers on the TheSeedInvestor.com website applicable to all content provided by TSI, wherever published or re-published: http://theseedinvestor.com/about/disclaimer.
This news release/advertorial is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed on this website unless you can afford to lose your entire investment. Also, investing in small-cap and micro-cap securities is highly speculative and carries an extremely high degree of risk. This website makes no recommendation that the securities of the companies profiled or discussed on this website should be purchased, sold or held by viewers that learn of the profiled companies through our website. Compensation: A thirty-six-thousand-dollar investor relations budget is being managed by The Seed Investor. Any funds leftover after expenses for research, overhead, advertising and public relations related to InMed Pharmaceuticals Inc. (ticker symbol (CSE: IN; OTCQB: IMLFF) will be considered profit. The Seed Investor and/or entities related to The Seed Investor hold shares in (CSE: IN; OTCQB: IMLFF) and intend to sell those shares. Please review all investment decisions with a licensed investment advisor.
Read More
Is InMed Pharmaceuticals (OTCQB:IMLFF) The Next Big Thing In Cannabis?
